Shock wave therapy: ED cure or unproven treatment? - Urology …
2019年8月6日 · Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important unanswered questions, including which patients are ideal candidates and which protocol and devices are best. Without answers, offering the ED treatment ...
New recurrent UTI guideline: What urologists need to know
2019年10月7日 · Recurrent urinary tract infections (rUTIs), defined as two culture-proven UTIs in a 6-month period or three culture-proven events in 1 year, make up a large percentage of UTIs seen in urologic practices. Although the American Urological Association has developed a guideline previously, the current climate of antibiotic overuse and resultant ...
Long-term results of Rezum therapy for patients with large prostates
December 23, 2021. Long-term results of Rezum therapy for patients with large prostates. Author (s): Janelle Hart. Patients with large prostates (LP), defined as greater than 80 grams, are generally limited to certain procedures such as a prostatectomy or transurethral resection of the prostate (TURP) when surgery is required.
Dr. Elterman discusses Rezum and Aquablation for patients with BPH
2021年9月10日 · Dean Elterman, MD. At the 2021 American Urological Association annual meeting, Dean Elterman, MD, MSc, FRCSC, presented the studies “Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: large, multi-center cohort,” 1 and “Pooled analysis of bladder function post-Aquablation.” 2.
5-year Rezum study results show low rates of erectile and …
2021年9月23日 · What we can say about MIST, minimally invasive surgical treatment, and in the current guidelines the real players are Rezum and UroLift, there is reliable data to 5 years, but not beyond. And we know about retreatment rates within 5 years. Surgical retreatment rates in terms of Rezum at 5 years is 4.4%, relatively low.
Advancements in Minimally Invasive Surgical Options for the …
2022年3月31日 · Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate affecting more than 40 million men in the United States with an associated prevalence that increases from 40% to 80% among men 50 to 70 years of age, respectively. 1,2 Progression of BPH leads to the subsequent development of lower urinary tract symptoms (LUTS), which …
Dr. Chee summarizes latest Optilume data in patients with urethral ...
Article. November 9, 2021. Dr. Chee summarizes latest Optilume data in patients with urethral strictures. Author (s): Urology Times staff. "Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD. At the 2021 International Continence Society Meeting, Justin ...
How to manage testicular/groin pain: Medical and surgical ladder
2014年7月24日 · Medical therapy for the treatment of chronic scrotal content pain is challenging and typically empirical. Antibiotics can be prescribed initially if an infectious etiology is suspected. Nonsteroidal anti-inflammatory drugs can be offered should there be an inflammatory component of the pain syndrome.
How testosterone therapy use in men with prostate cancer has …
2023年1月5日 · According to Khera, the need for testosterone might be greater among prostate cancer patients. “Specifically for men with a history of prostate cancer, testosterone therapy can improve recovery of erectile function following…treatment. Testosterone plays a key role in overall erectile function.”. Although every case is different ...
177Lu-PSMA-617 meets rPFS end point in phase 3 trial for mCRPC
2023年10月23日 · Results from the phase 3 PSMAfore (NCT04689828) trial indicate that treatment with 177 -Lu-PSMA [prostate-specific membrane antigen]-617 (Pluvicto) met its primary end point of radiographic progression-free survival (rPFS) and showed a favorable safety profile in patients with metastatic castration-resistant prostate cancer (mCRPC) who were ...